Relypsa Overview

  • Founded
  • 2007
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 400
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $1.53B
Latest Deal Amount

Relypsa General Information

Description

Operator of a biopharmaceutical company. The company is focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are overlooked and under treated and can be addressed in the gastrointestinal tract.

Contact Information

Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Parent Company
Primary Office
  • 100 Cardinal Way
  • Redwood City, CA 94063
  • United States
+1 (650) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Relypsa Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 01-Sep-2016 $1.53B 00000 00.000 Completed Profitable
10. Debt - General 03-May-2016 00000 00000 Completed Profitable
9. Secondary Transaction - Open Market 31-Mar-2016 00000 Completed Generating Revenue/Not Profitable
8. Secondary Transaction - Open Market 31-Mar-2015 00000 Completed Generating Revenue/Not Profitable
7. Debt - General 02-Jun-2014 0000 00000 Completed Profitable
6. Secondary Transaction - Open Market 17-Apr-2014 00000 Completed Generating Revenue/Not Profitable
5. IPO 15-Nov-2013 000.00 00000 00000 Completed Profitable
4. Later Stage VC (Series C) 15-Aug-2012 0000 00000 00000 Completed Profitable
3. Early Stage VC (Series B2) 28-Jul-2011 $35M $113M 00000 Completed Profitable
2. Early Stage VC (Series B1) 07-Sep-2010 $35M $78M 0000 Completed Profitable
To view Relypsa’s complete valuation and funding history, request access »

Relypsa Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C-2 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.00
Series C-1 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B-2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A-1 55,377,880 $0.001000 8% $1 $1 1x $1 11.2%
Series A 55,377,880 $0.001000 8% $1 $1 1x $1 11.2%
To view Relypsa’s complete cap table history, request access »

Relypsa Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biopharmaceutical company. The company is focused on the discovery, development and commercialization of p
Biotechnology
Redwood City, CA
400 As of 2016
00000
0.000 0000-00-00
000000&0 00000

0000000

consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nu
0000 000000000
Kulmbach, Germany
00 As of 0000
000000000000

00000

r incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ul
0000000000000
Thousand Oaks, CA
00000 As of 0000
00.000
000000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Relypsa Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Axolabs Private Equity-Backed Kulmbach, Germany 00 000000000000
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
00 000000 Corporate Backed or Acquired Coppell, TX 000 00000 000000&0 00000
000000 Formerly VC-backed Monrovia, CA 000 00000 00000000 00000
You’re viewing 5 of 17 competitors. Get the full list »

Relypsa Executive Team (18)

Name Title Board Seat Contact Info
Ronald Kransnow JD Senior Vice President & General Counsel
Umar Hayat Ph.D Senior Director, Product Development & Manufacturing
Mary Corbett Senior Vice President, Human Services
Jennifer Chung Vice President, Commercial
Sylvia Wheeler Vice President, Investor Relations and Corporate Affairs
You’re viewing 5 of 18 executive team members. Get the full list »

Relypsa Board Members (18)

Name Representing Role Since
Daniel Spiegelman Self Chairman 000 0000
David McGirr Self Board Member 000 0000
Gerrit Klaerner Ph.D Self Consultant & Board Member 000 0000
Helen Torley Self Board Member 000 0000
John Butler Self Board Member 000 0000
You’re viewing 5 of 18 board members. Get the full list »

Relypsa Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Relypsa Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
5AM Ventures Venture Capital Minority 000 0000 000000 0
Amgen Corporation Minority 000 0000 000000 0
Delphi Ventures Venture Capital Minority 000 0000 000000 0
Mediphase Venture Partners Venture Capital Minority 000 0000 000000 0
New Leaf Venture Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »